Q. Rehman

发表

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis

N. Lane, G. Modin, T. Lang, 2003, Osteoporosis International.

Effect of glucocorticoids on bone density.

N. Lane, Q. Rehman, 2003, Medical and pediatric oncology.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

R. Moots, P. Emery, D. Mevorach, 2017, The Lancet.

Parathyroid hormone treatment for glucocorticoid-induced osteoporosis

N. Lane, Q. Rehman, Qaiser Rehman, 2000 .

When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations.

K. Sack, Q. Rehman, Kenneth E. Sack, 1999, Postgraduate medicine.

Osteoporosis in the rheumatic disease patient

N. Lane, Q. Rehman, Nancy E. Lane, 2002, Lupus.

Bone loss: Therapeutic approaches for preventing bone loss in inflammatory arthritis

N. Lane, Q. Rehman, Qaiser Rehman, 2001, Arthritis research.

Cardiomyopathy in association with selenium deficiency: a case report.

W. Casscells, Q. Rehman, S. Yusuf, 2002, JPEN. Journal of parenteral and enteral nutrition.

Getting control of osteoarthritis pain. An update on treatment options.

N. Lane, Q. Rehman, Nancy E. Lane, 1999, Postgraduate medicine.

Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy.

N. Lane, G. Modin, T. Lang, 2002, Arthritis and rheumatism.

Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment.

F. Wolfe, J. Kremer, N. Lane, 2001, Journal of Rheumatology.